Zevra Therapeutics, Inc. Asset Impairment Charges
Zevra Therapeutics, Inc. (ZVRA) reported Asset Impairment Charges of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2020-02-28
- Zevra Therapeutics, Inc. asset impairment charges for fiscal 2019 was $0.00.
- Zevra Therapeutics, Inc. asset impairment charges for fiscal 2018 was $0.00.
- Zevra Therapeutics, Inc. asset impairment charges for fiscal 2017 was $0.00.
- Zevra Therapeutics, Inc. asset impairment charges for fiscal 2016 was $0.00.
| Period end | Asset Impairment Charges 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-28 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-28 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-01 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-30 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-30 |
| 2014-12-31 | $0.00 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |